Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor

[Image: see text] Inhibition of mutant IDH1 is being evaluated clinically as a promising treatment option for various cancers with hotspot mutation at Arg(132). Having identified an allosteric, induced pocket of IDH1(R132H), we have explored 3-pyrimidin-4-yl-oxazolidin-2-ones as mutant IDH1 inhibito...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:ACS Med Chem Lett
المؤلفون الرئيسيون: Cho, Young Shin, Levell, Julian R., Liu, Gang, Caferro, Thomas, Sutton, James, Shafer, Cynthia M., Costales, Abran, Manning, James R., Zhao, Qian, Sendzik, Martin, Shultz, Michael, Chenail, Gregg, Dooley, Julia, Villalba, Brian, Farsidjani, Ali, Chen, Jinyun, Kulathila, Raviraj, Xie, Xiaoling, Dodd, Stephanie, Gould, Ty, Liang, Guiqing, Heimbach, Tycho, Slocum, Kelly, Firestone, Brant, Pu, Minying, Pagliarini, Raymond, Growney, Joseph D.
التنسيق: Artigo
اللغة:Inglês
منشور في: American Chemical Society 2017
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5641959/
https://ncbi.nlm.nih.gov/pubmed/29057061
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.7b00342
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة